H5N1 vaccines: how prepared are we for a pandemic?

Lancet

Volumn 368, Issue 9540, 2006, Pages 965-966

  Stephenson, Iain ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HN PROTEIN; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; VIRUS VACCINE;

ANTIBODY DETECTION; ARTICLE; AVIAN INFLUENZA; BIRD; COMPARATIVE STUDY; DRUG FORMULATION; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MORTALITY; POPULATION; POULTRY; PRIORITY JOURNAL; VACCINATION; VACCINE PRODUCTION; VIRION; VIRUS;

EID: 33748447832     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69340-9     Document Type: Note

References (14)

1. Epidemic and Pandemic Alert and Response. Avian influenza (Aug 29, 2006). http://www.who.int/csr/disease/avian_influenza/en/ (accessed Aug 25, 2006)
2. Tumpey T., Basler C., Aguilar P., et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310 (2005) 77-80
3. Lin J., Zhang J., Dong X., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006). published online Sept 7. DOI:10.1016/S0140-6736(06)69294-5
4. Stephenson I., Nicholson K., Wood J., Zambon M., and Katz J. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 4 (2004) 499-509
5. Furminger I. Vaccine production. In: Nicholson K., Webster R., and Hay A. (Eds). Textbook of influenza (1998), Blackwell Science, Oxford 324-332
6. Fedson D. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Pub Health Policy 26 (2005) 4-29
7. Treanor J., Campbell J., Zangwill K., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1345-1351
8. Bresson J., Perronne C., Launay O., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
9. Nicholson K., Tyrell D., Harrison P., et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7 (1979) 123-136
10. Wright P., Thompson J., Vaughn W., Folland D., Sell S., and Karzon D. Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age related antigenicity and reactogenicity. J Infect Dis 136 (1977) S731-S741
11. Nicholson K., Colegate A., Podda A., et al. Safety and antigenicity of nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 (2001) 1937-1943
12. Stephenson I., Bugarini R., Nicholson K., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses following vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 (2005) 1210-1215
13. Rowe T., Abernathy R., Hu-Primmer J., et al. Detection of antibody to avian influenza (H5N1) virus in human sera by using a combination of serological assays. J Clin Microbiol 37 (1999) 937-943
14. Brown D. $1 billion awarded for flu vaccine. Washington Post (May 5, 2006). http://www.washingtonpost.com/wp-dyn/content/article/2006/05/04/AR2006050401879.html (accessed Aug 25, 2006)